Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics

Triple-negative breast cancer is one of the most lethal cancers. Chemotherapeutics for targeting CDK4 and CDK6 like Palbociclib (PAB) in triple-negative breast cancer was widely explored. However, poor bioavailability and severe side effects profile limiting its clinical usage in the field of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kommineni, Nagavendra, Paul, David, Saka, Raju, Khan, Wahid, Nanjappan, Satheeshkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428924/
https://www.ncbi.nlm.nih.gov/pubmed/36051857
http://dx.doi.org/10.7150/ntno.76370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428924/
https://www.ncbi.nlm.nih.gov/pubmed/36051857
http://dx.doi.org/10.7150/ntno.76370

Ejemplares similares